← All trials
NCT05722925
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 4, 2023
- Primary completion
- Jan 1, 2025
- Completion date
- Jan 1, 2026
- First posted
- Feb 10, 2023
- Last posted
- Oct 16, 2023
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OHSU Knight Cancer InstituteLead sponsor
- Blue Earth DiagnosticsCollaborator
- Oregon Health and Science UniversityCollaborator
- OHSU Knight Cancer InstituteOverall official - principal investigator
- OHSU Knight Cancer InstituteReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.